Skip to main content
Fig. 3 | BMC Cancer

Fig. 3

From: High tumor budding is a strong predictor of poor prognosis in the resected perihilar cholangiocarcinoma patients regardless of neoadjuvant therapy, showing survival similar to those without resection

Fig. 3

Patient survival according to tumor budding in patients with or without neoadjuvant therapy. a, b Disease specific survival (DSS) and Recurrence free survival (RFS) in patients with neoadjuvant therapy. c, d DSS and RFS in patients without neoadjuvant therapy. In patients with neoadjuvant therapy, patients in high TB group had significantly poor survival as compared to patients in low TB group (p < 0.001 in DSS, p = 0.001 in RFS). Similarly, in patients without neoadjuvant therapy, patients in high TB group had significantly poor DSS and had a tendency with poor RFS, as compared to patients in low TB group (p = 0.004 in DSS, p = 0.127 in RFS). *6 patients with neoadjuvant therapy and 5 patients without neoadjuvant therapy with R2 resection (distant metastasis or cancer positive surgical margin) were excluded from RFS study

Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us